Transcriptomics

Dataset Information

0

Pharmacological inhibition of tyrosine kinase 2 preserves interferon-λ-mediated protection (neutrophils)


ABSTRACT: Treating inflammatory diseases with Janus kinase 1/2 (JAK1/2) inhibitors bears the risk that patients acquire viral infections due to unwanted immune suppression. Tyrosine kinase 2 (TYK2), a JAK family member, is required for type I interferon (IFN-α/β) signaling, but its role in type III IFN (IFN-λ) signaling is still under debate. We found that the selective TYK2 inhibitor BMS-986165 blocked potentially noxious type I IFN signaling without altering IFN-λ-mediated gene expression. We show that epithelial cells do not require TYK2 for IFN-λ-mediated signaling or antiviral protection. Lack of TYK2 diminished IFN-α-induced protection against lethal influenza virus infection of mice, but did not impair IFN-λ-mediated antiviral protection. Our findings suggest that selective TYK2 inhibitors likely represent a superior treatment option for type I interferonopathies than broadly acting JAK1/2 inhibitors, as selective TYK2 inhibitors may counteract inflammatory responses without abolishing the beneficial antiviral effects of IFN-λ.

ORGANISM(S): Mus musculus

PROVIDER: GSE146103 | GEO | 2021/04/09

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-04-09 | GSE146102 | GEO
2024-05-28 | PXD045482 | Pride
2023-07-20 | PXD031384 | Pride
2015-01-08 | E-GEOD-64735 | biostudies-arrayexpress
2015-01-08 | GSE64735 | GEO
2023-09-12 | GSE242068 | GEO
2023-09-12 | GSE242170 | GEO
2016-07-20 | GSE84560 | GEO
2016-07-20 | GSE84565 | GEO
2020-10-19 | GSE105417 | GEO